Trial Profile
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Seribantumab (Primary) ; Cabazitaxel; Carboplatin; Gemcitabine; Pemetrexed
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merrimack Pharmaceuticals
- 03 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Nov 2013 Planned End Date changed from 1 Feb 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 05 Jun 2013 Results in 43 patients presented at the 2013 American Society of Clinical Oncology Annual Meeting, according to Merrimack Pharmaceuticals media release.